Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose by more than 4% Kailimei® research results were recently displayed on a poster at the ESMO annual conference

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by more than 4%. As of press release, it had risen 4.21% to HK$10.9, with a turnover of HK$14.04 million.

According to the news, recently, Keji Pharmaceutical-B announced that the preliminary results of clinical trials (CT041-CG4010, NCT06857786) conducted in China for claudin18.2 positive/adjuvant treatment of patients with Claudin18.2 positive/gastroesophagastric junction cancer patients after ^radical treatment (,) conducted in China on October 25, 2026 (CT041 On Sunday) 12:00-12:45 Central European Summer Time (CEST), a poster presentation will be held at the 2026 European Society of Medical Oncology (ESMO) Annual Meeting.

^{Previously, Keji Pharmaceutical-B received a notice from the National Drug Administration (NMPA) on June 22, 2026 to approve its self-developed Claudin18.2 autologous humanized CAR-T cell treatment product, the marketing application for a new drug for the treatment of Claudin18.2 positive, human epidermal growth factor receptor 2 (HER2) negative, and advanced gastroesophageal junction adenocarcinoma where at least second-line treatment failed. According to reports, Kalimei® is the world's first CAR-T cell therapy product approved for solid tumor treatment.}